Role of TGFβ3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of tumour-associated mortality worldwide, but no significant improvement in treating HCC has been reported with currently available systemic therapies. Immunotherapy represents a new frontier in tumour therapy. Therefore, the immunobiology of hepatocarcinoma has been under intensive investigation. Decoy receptor 3 (DcR3), a member of the tumour necrosis factor receptor (TNFR) superfamily, is an immune suppressor associated with tumourigenesis and cancer metastasis. However, little is known about the role of DcR3 in the immunobiology of hepatocarcinoma. In this study, we found that overexpression of DcR3 in HCC is mediated by the TGFβ3-Smad-Sp1 signalling pathway, which directly targets DcR3 promoter regions. Moreover, overexpression of DcR3 in HCC tissues is associated with tumour invasion and metastasis and significantly promotes the differentiation and secretion of Th2 and Treg cells while inhibiting the differentiation and secretion of Th1 cells. Conversely, knockdown of DcR3 expression in HCC significantly restored the immunity of CD4 + T cells. Inhibition of DcR3 expression may provide a novel immunotherapeutic approach to restoring immunity in HCC patients.

MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression

“…Every year, the government has provided millions of money to the studies of HCC, and sorafenib and regorafenib have made great contributions for the therapy of HCC. What's more, many studies have focused the mechanisms of HCC progression and metastasis [26][27][28][29]. Our study based on the clinical samples databases, and identified a new pathway connected to the progression of HCC, is another sample to study HCC progression for better therapy of HCC patients.…”

Astragalus polysaccharides attenuate pulmonary�fibrosis by inhibiting the epithelial-mesenchymal�transition and NF-κB pathway activation

“…TGF-β1 activates fibroblasts and transforms them into myofibroblasts (2,3). Numerous studies reported that TGF-β1 is a key fibrogenic factor, which can induce EMT in PF (27). Subsequently, inhibition of EMT through the TGF-β1 pathway may be considered as a potential therapeutic option for IPF.…”

Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges

“…Chaoul et al (2020) CD4+T cell The immune mechanism Knockdown of DCR3 expression in HCC significantly restored the immunity of CD4+T cells. Inhibition of DCR3 expression may provide a novel immunotherapy approach to restore immunity in HCC patients Zhu et al (2019) CD4+T cell The immune mechanism Activated CD4+T cells from HCC stimulate macrophages to produce C-X-C motif chemokine 10(CXCL10). CXCL10 binds to the CXC chemokine receptor 3 on B cells and signals them through extracellular signal-regulated kinases, making them plasma cells that produce IgG.…”